Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
210 articles by Michael Gibney
-
Big Pharma earnings hang hope on the next generation of blockbusters
Oct. 31, 2024 -
2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Oct. 30, 2024 -
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
Oct. 29, 2024 -
2024 PharmaVoice 100s: Biotech Pathfinders
Oct. 23, 2024 -
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Oct. 22, 2024 -
As new Alzheimer’s biomarkers come into play, here’s where the money is going
Oct. 17, 2024 -
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
Oct. 15, 2024 -
Regeneron takes the long-haul approach to oncology, stumbles and all
Oct. 10, 2024 -
Flu vaccination rates are falling despite record child deaths. Can innovation save the day?
Oct. 3, 2024 -
Top pharma and biotech conferences 2025
Oct. 1, 2024 -
Roivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Sept. 26, 2024 -
Want better cancer treatments? Make biopharma more like Silicon Valley
Sept. 24, 2024 -
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
Sept. 19, 2024 -
How a radiopharma up-and-comer builds momentum in a surging space
Sept. 17, 2024 -
How Lilly’s sustainability goals come face to face with massive growth
Sept. 12, 2024 -
A new way of determining a drug’s value — with health equity in mind
Sept. 10, 2024 -
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
Sept. 4, 2024 -
Their Alzheimer’s treatment worked — but shares fell anyway
Aug. 29, 2024 -
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
Aug. 27, 2024 -
23andMe inches closer to cancer immunotherapy, guided by its genetic database
Aug. 20, 2024 -
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
Aug. 15, 2024 -
A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients
Aug. 13, 2024 -
Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half
Aug. 8, 2024 -
Pfizer, GSK and Moderna execs remain optimistic about RSV vaccines despite CDC blowback
Aug. 6, 2024 -
7 years after launch, Sanofi’s Dupixent is set for a megablockbuster run
July 30, 2024